Search

Displaying results 381 - 390 of 4539 in total
  1. Drug

    AstraZeneca COVID-19 Vaccine

    go.drugbank.com/drugs/DB15656
    ApprovedInvestigational

    [L12669] The trial is taking place in the UK, where the vaccine will be administered intramuscularly to healthy adult volunteers between the ages of 18 and 55.[L12669] … development and distribution deal with AstraZeneca in May 2020[L32659] which paved the way for the vaccine's subsequent approval and usage in dozens of regions across the globe, including Canada, Mexico, the UK

  2. Drug

    Rizatriptan

    go.drugbank.com/drugs/DB00953
    ApprovedInvestigational

    [L46018] Used in the treatment of migraines, rizatriptan was first approved in the US in 1998.

  3. Drug

    Ferric maltol

    go.drugbank.com/drugs/DB15598
    ApprovedInvestigational

    [L10974] On December 22, 2025, the FDA expanded this indication to include pediatric patients aged 10 years and older. [L54873,L54878]

  4. Drug

    Teduglutide

    go.drugbank.com/drugs/DB08900
    ApprovedInvestigational

    It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology. … Teduglutide differs from GLP-2 by one amino acid (alanine is substituted by glycine).

  5. Drug

    Nedosiran

    go.drugbank.com/drugs/DB17635
    ApprovedInvestigational

    [A261685] Nedosiran was approved by the FDA on October 2<sup>nd</sup>, 2023, under the brand name RIVFLOZA to lower urinary oxalate levels in children 9 years of age and older and adults with primary

  6. Drug

    Tenofovir alafenamide

    go.drugbank.com/drugs/DB09299
    ApprovedInvestigational

    Tenofovir alafenamide is a novel [tenofovir] prodrug developed in order to improve renal safety when compared to the counterpart [tenofovir disoproxil]. … [T239] Tenofovir alafenamide is an alanine ester form characterized for presenting low systemic levels but high intracellular concentration.

  7. Drug

    Icotrokinra

    go.drugbank.com/drugs/DB21724
    ApprovedInvestigational

    [L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108] … It was jointly discovered and developed by Protagonist and Johnson & Johnson[L56118] and provides a novel, oral treatment option for patients requiring systemic therapy for plaque psoriasis.

  8. Drug

    Prasterone

    go.drugbank.com/drugs/DB01708
    ApprovedInvestigationalNutraceutical

    In Canada, a prescription is required to buy DHEA. … Prasterone, also known as dehydroepiandrosterone (DHEA) is a major C19 steroid produced by the adrenal cortex. It is also produced in small quantities in the testis and the ovary.

  9. Drug

    Avelumab

    go.drugbank.com/drugs/DB11945
    ApprovedInvestigational

    [A261496] Avelumab was first approved by the FDA on March 23, 2017. … [A261496] On September 18 and December 18 of the same year, it was also granted approval by EMA [L48126] and Health Canada,[L48171] respectively.

  10. Drug

    Clarithromycin

    go.drugbank.com/drugs/DB01211
    ApprovedInvestigational

    Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit.

    Products: KLARICID® UD, ARLECYN-K